SCHEMBL7009288

SCHEMBL7009288

CCOC(=O)c1cccc(-n2cc(Cc3cncnc3)c(=O)[nH]c2=S)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.41
ALOX15 P16050 1/20 0.40
ATM Q13315 1/20 0.39
PDE3B Q13370 3/20 0.39
PDE3A Q14432 3/20 0.39
MAT2A P31153 1/20 0.39
KDM4E B2RXH2 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
ALDH1A1 P00352 2/20 0.38
LMNA P02545 2/20 0.38
NPBWR1 P48145 1/20 0.38
MCHR1 Q99705 1/20 0.38
PRKCA P17252 1/20 0.38
GSK3B P49841 1/20 0.38
ESRRA P11474 1/20 0.37
MAPT P10636 1/20 0.37
PPARG P37231 1/20 0.37
RAB9A P51151 1/20 0.37
NCOA2 Q15596 1/20 0.37
NCOA1 Q15788 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7530971 0.89 ALDH1A1 (0.43) ALOX15PDE3BPDE3ASMN1; SMN2ALDH1A1
SCHEMBL7010694 0.78 RECQL (0.42) ALOX15PDE3BPDE3ASMN1; SMN2ALDH1A1
SCHEMBL7529761 0.77 PLA2G7 (0.41) KDM4EALDH1A1MAPTRAB9A
SCHEMBL7524218 0.77 ALDH1A1 (0.41) ALOX15PDE3BPDE3AKDM4ESMN1; SMN2
SCHEMBL7010646 0.77 PLA2G7 (0.39)
SCHEMBL7012186 0.74 PLA2G7 (0.35) PDE3BPDE3AKDM4ESMN1; SMN2ALDH1A1
SCHEMBL4784146 0.74 RAB9A (0.62) ALOX15SMN1; SMN2ALDH1A1LMNAMAPT
SCHEMBL7008913 0.74 PLA2G7 (0.57)
SCHEMBL7093582 0.73 KMT2A (0.42) ALOX5PDE3BPDE3ASMN1; SMN2ALDH1A1
SCHEMBL7011218 0.71 PLA2G7 (0.44) LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1028955-B1 PYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SMITHKLINE BEECHAM PLC (GB) 2003-07-16 EP disclosed
US-20020120139-A1 Pyrimidinone compounds and pharmaceutical compositions containing them HICKEY DEIRDRE MARY BERNADETTE (GB) 2002-08-29 US disclosed
US-6417192-B1 DRUGS WITH PYRIMIDONE COMPOUNDS INHIBITORS OF THE ENZYME LDL PLA.SUB.2 AND THEREFORE OF USE IN TREATING ATHEROSCLEROSIS. SMITHKLINE BEECHAM P.L.C. (GB) 2002-07-09 US disclosed
EP-1175409-A1 PYRIMIDINONES DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS SMITHKLINE BEECHAM PLC (GB) 2002-01-30 EP disclosed
WO-2000068208-A1 PYRIMIDINONES DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS SMITHKLINE BEECHAM PLC (GB) 2000-11-16 WO disclosed
EP-1028955-A1 PYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SmithKline Beecham p.l.c. (GB) 2000-08-23 EP disclosed
WO-1999024420-A1 PYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SMITHKLINE BEECHAM PLC (GB) 1999-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120139-A1 Pyrimidinone compounds and pharmaceutical compositions containing them PLA2G7, PLA2G1B, PLA2G4C ALOX5 40/4885ALOX15 66/4885ATM 2580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.